NEW YORK (GenomeWeb News) – Epigenomics today reported a 67 percent drop year over year in first-quarter revenues.

For the three months ended March 31, the German molecular diagnostics firm reported €200,000 ($258,892) in revenues, down from €600,000 a year ago, when it received a payment from Qiagen for a non-exclusive license to Epigenomics' methylated Septin-9 biomarker.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.